期刊
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
卷 43, 期 2, 页码 103-109出版社
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hys200
关键词
cancer biomarker; personalized medicine; early detection; proteomics
类别
资金
- National Cancer Center Research and Development Fund [23-A-38, 23-A-11]
Cancer biomarkers for the early detection of malignancies and selection of therapeutic strategies have been requested in the clinical field. Accurate and informative cancer biomarkers hold significant promise for improvements in the early detection of disease and in the selection of the most effective therapeutic strategies. Recently, significant progress in the comprehensive analysis of the human genome, epigenome, transcriptome, proteome and metabolome has led to revolutionary changes in the discovery of cancer biomarkers. The Human Proteome Organization has launched a global Human Proteome Project to map the entire human protein set. The Human Proteome Project research group has focused on three working proteomic pillarsumass spectrometry-based, antibody-based and knowledge-based proteomicsuand each of these technologies is advancing rapidly. In this review, we introduce the proteomic platforms that are currently being used for cancer biomarker discovery, and describe examples of novel cancer biomarkers that were identified with each proteomic technology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据